Breast

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
ARTEMISFeasibility Study of the Role of Stereotactic Body Radiotherapy for the Treatment of Early Stage Breast CancerKim, Dr Do-hoonOpenNCT02065960
CompLEEment-1 An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease Bordeleau, Dr LouiseOpenNCT02941926
MAC.20Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast CancerBordeleau, Dr LouiseOpenNCT02750826
OCOG-2012-LUMINAA Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer (LUMINA)Whelan, Dr TimothyOpenNCT01791829
OCOG-2015-OPARA Phase II Randomized Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation (OPAR)Kim, Dr Do-hoonOpenNCT02637024
OCOG-2016-DUCHESSEvaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients with Low/Intermediate Risk DCISKong, Dr IwaOpenNCT02766881
OCOG-2016-PETABCImpact of 18F-FDG PET-CT versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast CancerDhesy, Dr Bindi OpenNCT02751710
MA.36 A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapyBordeleau, Dr LouiseOpenNCT02032823
MA.37PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (MA.37) Bordeleau, Dr LouiseOpenNCT02513394
RUBYReducing the burden of breast cancer in young womenHodgson, Dr NicoleOpen
Download PDF